During his time at Rhythm Pharmaceuticals, Dr. Gottesdiener’s wealth was closely tied to the company’s stock performance. In 2019, he was granted options to buy 225,000 shares, which illustrated a high level of investment in the company’s success. His overall...

During his time at Rhythm Pharmaceuticals, Dr. Gottesdiener’s wealth was closely tied to the company’s stock performance. In 2019, he was granted options to buy 225,000 shares, which illustrated a high level of investment in the company’s success. His overall compensation included a $2.75 million bonus, signaling major achievements in corporate goals. However, by 2020, his holdings and wealth began a notable shift following his separation from the company after the NDA filing with the FDA. This suggests that much of his financial stake was contingent on the full realization of Rhythm’s market potential, reflecting the high stakes involved in biotech leadership.